Karin Meyer - Sprint Bioscience Director
| SPRINT Stock | SEK 1.30 0.04 2.99% |
Director
Ms. Karin Meyer no longer serves as Independent Director of Sprint Bioscience AB effective as of May 15, 2019. She has held the position since May 20, 2015. She is also CEO of the Swedish Pharmaceutical Society. She has extensive experience in the pharmaceutical industry where she has worked with both research and development and business development. Before she joined the Swedish Pharmaceutical Society she was CEO of PCG Clinical Services AB and PCG Solutions AB and also the business manager at Uppsala University. Before that she worked for 10 years at Quintiles with clinical trials in Phase 1 and was more recently CEO of Quintiles Scandinavia. She has also worked at AstraZeneca in health economics in clinical trials and as administrator at the Medical Products Agency. She is also a Member of the Boards of several Life Science companies. since 2015.
| Tenure | 9 years |
| Phone | 46 84 11 44 55 |
| Web | https://www.sprintbioscience.com |
Sprint Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.5879) % which means that it has lost $0.5879 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0926) %, meaning that it generated substantial loss on money invested by shareholders. Sprint Bioscience's management efficiency ratios could be used to measure how well Sprint Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. Sprint Bioscience AB (SPRINT) is traded on Stockholm Exchange in Sweden and employs 34 people.Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 |
Sprint Bioscience Leadership Team
Elected by the shareholders, the Sprint Bioscience's board of directors comprises two types of representatives: Sprint Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sprint. The board's role is to monitor Sprint Bioscience's management team and ensure that shareholders' interests are well served. Sprint Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sprint Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AnneMarie Wenthzel, Director of Sales and Marketing | ||
| Martin Andersson, Founder and Director of Discovery Projects | ||
| Ingemar Kihlstrom, Director | ||
| Fredrik Lehmann, Director | ||
| Charlotta Liljebris, Director | ||
| Rune Nordlander, Chairman of the Board | ||
| Mathias Skalmstad, Chief Officer | ||
| Par Nordlund, Director | ||
| Kenth Hallberg, Founder and Director of Structural Chemistry | ||
| JanErik Nystrom, Director | ||
| Karin Mayer, Director | ||
| Jessica Martinsson, Director Medicinal Chemistry, Director | ||
| Karin Meyer, Director | ||
| Pr Nordlund, Founder and Director | ||
| Jessica MSc, Founder, Director of Medicinal Chemistry and Director | ||
| Anders Aberg, CEO | ||
| Prof MBA, Chief Officer |
Sprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sprint Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (76.00) % | |||
| Current Valuation | 24.98 M | |||
| Shares Outstanding | 69.8 M | |||
| Shares Owned By Insiders | 35.31 % | |||
| Shares Owned By Institutions | 2.59 % | |||
| Price To Earning | 32.79 X | |||
| Price To Book | 2.61 X | |||
| Price To Sales | 27.09 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sprint Bioscience AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Sprint Stock analysis
When running Sprint Bioscience's price analysis, check to measure Sprint Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sprint Bioscience is operating at the current time. Most of Sprint Bioscience's value examination focuses on studying past and present price action to predict the probability of Sprint Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sprint Bioscience's price. Additionally, you may evaluate how the addition of Sprint Bioscience to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |